NEW YORK (GenomeWeb News) — The US Food and Drug Administration will use Entelos’ computer modeling software to assess the safety and efficacy of a specific set of cardiovascular drugs, the company said today.
 
Under the agreement, FDA will use the company’s Cardiovascular PhysioLab, which is a large-scale computer simulation of cholesterol regulation, atherogenesis, and cardiovascular risk. The Foster City, Calif.-based firm would not disclose the compound class and drug set that will be evaluated.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.